CoChat
Sign Up
Cited by 160Viral Infections and Outbreaks ResearchViral Infections and VectorsVirology and Viral Diseases

Marburg virus disease: a summary for clinicians

Open access
Kortepeter, Mark G., Dierberg, Kerry, Shenoy, Erica S., Cieslak, Theodore J.·2020·International Journal of Infectious Diseases
DOI 10.1016/j.ijid.2020.07.042PMC PMC7397931
Open this paper in CoChat — free account

Abstract

OBJECTIVES: This article summarizes the countermeasures for Marburg virus disease, focusing on pathogenesis, clinical features and diagnostics. There is an emphasis on therapies and vaccines that have demonstrated, through their evaluation in nonhuman primates (NHPs) and/or in humans, potential for use in an emergency situation. METHODS: A standardized literature review was conducted on vaccines and treatments for Marburg virus disease, with a focus on human and nonhuman primate data published in the last five years. More detail on the methods that were used is summarized in a companion methods paper. RESULTS: The study identified six treatments and four vaccine platforms that have demonstrated, through their efficacy in NHPs, potential benefit for treating or preventing infection in humans. CONCLUSION: Succinct summaries of Marburg countermeasures are provided to give the busy clinician a head start in reviewing the literature if faced with a patient with Marburg virus disease. Links to other authoritative sources of information are also provided.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ijid.2020.07.042

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Human-to-human transmission of MVD has been observed, primarily in household or healthcare settings with lack of infection protection and control measures, for example via contact with bodily fluids.

    “Human-to-human transmission has also been observed, primarily occurring in household or healthcare settings with a lack of infection protection and control measures, for example via contact with bodily fluids from an MVD patient (15,16).”

    From Marburg virus disease outbreaks, mathematical models, and disease parameters: a systematic review (2024) · cites this paper as [15]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 58

  1. Bauer M.P. Timen A. Vossen A.C.T.M. van Dissel J.T. Marburg haemorrhagic fever in returning travellers: an overview aimed at clinicians Clin Microbiol Infect 21 2019 e28 e31 24816494
  2. Bixler S.L. Bocan T.M. Wells K. Wetzel K.S. Van Tongeren S.A. Dong L. Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus Antivir Res 151 2018 97 104 29289666
  3. Borchert M. Mulangu S. Swanepoel R. Libande M.L. Tshomba A. Kulidri A. Serosurvey on household contacts of Marburg hemorrhagic fever patients Emerg Infect Dis 12 2006 433 439 16704781 PMC3291433
  4. Brauburger K. Hume A.J. Muhlberger E. Olejnik J. Forty-five years of Marburg virus research Viruses 4 2012 1878 1927 23202446 PMC3497034
  5. Coffin K.M. Liu J. Warren T.K. Blancett C.D. Kuehl K.A. Nichols D.K. Persistent Marburg virus infection in the testes of nonhuman primate survivors Cell Host Microbe 24 2018 405 416 30173956
  6. Cross R.W. Mire C.E. Feldmann H. Geisbert T.W. Post-exposure treatments for Ebola and Marburg virus infections Nat Rev Drug Discov 17 2018 418 434 29375139
  7. Daddario-DiCaprio K.M. Geisbert T.W. Stroher U. Geisbert J.B. Grolla A. Fritz E.A. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment Lancet 367 2006 1399 1404 16650649
  8. Dornemann J. Burzio C. Ronsse A. Sprecher A. De Clerck H. Van Herp M. First newborn baby to receive experimental therapies survives Ebola virus disease J Infect Dis 215 2017 171 174 10.1093/infdis/jiw493 28073857 PMC5583641 · DOI
  9. Duraffour S. Malvy D. Sissoko D. How to treat Ebola virus infections? A lesson from the field Curr Opin Virol 24 2017 9 15 28410486
  10. Dye J.M. Herbert A.S. Kuehne A.I. Barth J.F. Muhammad M.A. Zak S.E. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease Proc Natl Acad Sci USA 109 2012 5034 5039 10.1073/pnas.1200409109 22411795 PMC3323977 · DOI
  11. Falzarano D. Geisbert T.W. Feldmann H. Progress in filovirus vaccine development: evaluating the potential for clinical use Expert Rev Vaccines 10 1 2011 63 77 10.1586/erv.10.152 21162622 PMC3398800 · DOI
  12. Fischer W.A. Crozier I. Bausch D.G. Muyembe J.-J. Mulangu S. Diaz J.V. Shifting the paradigm – applying universal standards of care to Ebola virus disease N Engl J Med 380 2019 1389 1391 10.1056/NEJMp1817070 30970184 · DOI
  13. Gear J.S. Cassel G.A. Gear A.J. Trappler B. Clausen L. Meyers A.M. Outbreak of Marburg virus disease in Johannesburg Br Med J 4 1975 489 493 811315 PMC1675587
  14. Geisbert T.W. Daddario-Dicaprio K.M. Geisbert J.B. Reed D.S. Feldmann F. Grolla A. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses Vaccine 26 52 2008 6894 6900 10.1016/j.vaccine.2008.09.082 18930776 PMC3398796 · DOI
  15. Geisbert T.W. Geisbert J.B. Leung A. Daddario-DiCaprio K.M. Hensley L.E. Grolla A. Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus J. Virol 83 2009 7296 7304 19386702 PMC2704787
  16. Geisbert T. Bailey M. Geisbert J.B. Asiedu C. Roederer M. Grazia-Pau M. Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates J Virol 84 19 2010 10386 10394 10.1128/JVI.00594-10 20660192 PMC2937810 · DOI
  17. Geisbert T.W. Hensley L.E. Geisbert J.B. Leung A. Johnson J.C. Grolla A. Postexposure treatment of Marburg virus infections Emerg Infect Dis 16 2010 1119 1122 20587184 PMC3321919
  18. Geisbert T.W. Bailey M. Hensley L. Asiedu C. Geisbert J. Stanley D. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge J Virol 85 2011 4222 4233 10.1128/JVI.02407-10 21325402 PMC3126236 · DOI
  19. Heald A.E. Iversen P.L. Saoud J.B. Sazani P. Charleston J.S. Axtelle T. Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against Ebola virus and Marburg virus: results of two single-ascending-dose studies Antimicrob Agents Chemother 58 2014 6639 6647 10.1128/AAC.03442-14 25155593 PMC4249403 · DOI
  20. Heald A.E. Charleston J.S. Iversen P.L. Warren T.K. Saoud J.B. Al-Ibrahim M. AVI-7299 for Marburg virus in nonhuman primates and humans N Engl J Med 373 2015 339 348 10.1056/NEJMoa1410345 26200980 · DOI
  21. Henao-Restrepo A.M. Camacho A. Longini I.M. Watson C.H. Edmunds W.J. Egger M. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) Lancet 389 2017 505 518 28017403 PMC5364328
  22. Hoffmann M. Crone L. Dietzel E. Paijo J. Gonzalez-Hernandez M. Nehlmeier I. A polymorphism within the internal fusion loop of the Ebola virus glycoprotein modulates host cell entry J Virol 91 2017 1 14 PMC5391465 28228590
  23. Hutchinson K.L. Rollin P.E. Cytokine and chemokine expression in humans infected with Sudan Ebola virus J Infect Dis 196 2007 S357 S363 17940971
  24. Iversen P.L. Warren T.K. Wells J.B. Garza N.L. Mourich D.V. Welch L.S. Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections Viruses 4 2012 2806 2830 10.3390/v4112806 23202506 PMC3509674 · DOI
  25. Jacobs M. Rodger A. Bell D.J. Bhagani S. Cropley I. Filipe I. Late Ebola virus relapse causing meningoencephalitis: a case report Lancet 388 2016 498 503 10.1016/S0140-6736(16)30386-5 27209148 PMC4967715 · DOI
  26. Jones S.M. Feldmann H. Ströher U. Geisbert J.B. Fernando L. Grolla A. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses Nat Med 11 2005 786 790 15937495
  27. Kerber R. Lorenz E. Duraffour S. Sissoko D. Rudolf M. Jaeger A. Laboratory findings, compassionate use of favipiravir, and outcome in patients with Ebola virus disease, Guinea, 2015 –a retrospective observational study J Infect Dis 220 2 2019 195 202 10.1093/infdis/jiz078 30788508 PMC6581890 · DOI
  28. Kortepeter M.G. Bausch D.G. Bray M. Basic clinical and laboratory features of human filoviral fever J Infect Dis 204 2011 810 816 21987756
  29. Kuming B.S. Kokoris N. Uveal involvement in Marburg virus disease Br J Ophthalmol 61 1977 265 266 557985 PMC1042937
  30. Lu S. Wang S. Grimes-Serrano J.M. Current progress of DNA vaccine studies in humans Expert Rev Vaccines 7 2 2008 175 191 18324888
  31. Martin J.E. Sullivan N.J. Enama M.E. Gordon I.J. Roederer M. Koup R.A. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial Clin Vaccine Immunol 13 2006 1267 1277 16988008 PMC1656552
  32. Martini G.A. Marburg virus disease. Clinical syndrome Martini G.A. Siegert R. Marburg virus disease 1971 Springer-Verlag New York 1 9
  33. Martini G.A. Marburg virus disease Postgrad Med J 49 1973 542 546 10.1136/pgmj.49.574.542 4207635 PMC2495590 · DOI · Paper page
  34. Milligan I.D. Gibani M.M. Sewell R. Clutterbuck E.A. Campbell D. Plested E. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial JAMA 315 15 2016 1610 1623 10.1001/jama.2016.4218 27092831 · DOI
  35. Mire C.E. Geisbert J.B. Agans K.N. Satterfield B.A. Versteeg K.M. Fritz E.A. Durability of a vesicular stomatitis virus-based Marburg virus vaccine in nonhuman primates PLoS One 9 2014 e94355 10.1371/journal.pone.0094355 24759889 PMC3997383 · DOI
  36. Mire C.E. Geisbert J.B. Borisevich V. Fenton K.A. Agans K.A. Flyak A.I. Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody Sci Transl Med 9 384 2017 10.1126/scitranslmed.aai8711 PMC5719873 28381540 · DOI
  37. Mulangu S. Dodd L.E. Davey R.T. Mbaya O.T. Proschan M. Mukadi D. A randomized, controlled trial of Ebola virus disease therapeutics N Engl J Med 381 2019 2293 2303 10.1056/NEJMoa1910993 31774950 PMC10680050 · DOI
  38. National Center for Biotechnology Information Home – MeSH – NCBI 2019 Available from: https://www.ncbi.nlm.nih.gov/mesh. [Accessed 16 October 2019]
  39. Olejnik J. Muhlberger E. Hume A.J. Recent advances in marburgvirus research F1000Research 8 2019 1 13 PMC6530603 31131088
  40. Porter D.P. Weidner J.M. Gomba L. Bannister R. Blair C. Jordon R. Remdesivir (GS-5734) is efficacious in cynomolgus macaques infected with Marburg virus J Infect Dis 2020 10.1093/infdis/jiaa290 32479636 · DOI
  41. Reynolds P. Marzi A. Ebola and Marburg virus vaccines Virus Genes 53 2017 501 515 28447193 PMC7089128
  42. Riemenschneider J. Garrison A. Geisbert J. Jahrling P. Hevey M. Negley M. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus Vaccine 21 25–26 2003 4071 4080 12922144
  43. Rollin P.E. Bausch D.G. Sanchez A. Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus J Infect Dis 196 2007 S364 S371 17940972
  44. Rougeron V. Feldmann H. Grard G. Becker S. Leroy E.M. Ebola and Marburg hemorrhagic fever J Clin Virol 64 2015 111 119 10.1016/j.jcv.2015.01.014 25660265 PMC11080958 · DOI
  45. Schieffelin J.S. Shaffer J.G. Goba A. Gbakie M. Gire S.K. Colubri A. Clinical illness and outcomes in patients with Ebola in Sierra Leone N Engl J Med 371 2014 2092 2110 10.1056/NEJMoa1411680 25353969 PMC4318555 · DOI
  46. Sissoko D. Laouenan C. Folkesson E. M’Lebing A.B. Beavogui A.H. Baize S. Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea PLoS Med 13 3 2016 e1001967 10.1371/journal.pmed.1001967 26930627 PMC4773183 · DOI
  47. Smith L.M. Hensley L.E. Geisbert T.W. Johnson J. Stossel A. Honko A. Interferon-beta therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever J Infect Dis 208 2013 310 318 10.1093/infdis/jis921 23255566 PMC3685222 · DOI
  48. Stanley D.A. Honko A.N. Asiedu C. Trefry J.C. Lau-Kilby A.W. Johnson J.C. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge Nat Med 20 2014 1126 1129 25194571
  49. Stille W. Boehle E. Clinical course and prognosis of Marburg virus (“green monkey”) disease Martini G.A. Siegert R. Marburg virus disease 1971 Springer-Verlag New York 10 18
  50. Swenson D.L. Wang D. Luo M. Warfield K.L. Woraratanadharm J. Holman D.H. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections Clin Vaccine Immunol 15 2008 460 467 10.1128/CVI.00431-07 18216185 PMC2268273 · DOI
  51. Swenson D.L. Warfield K.L. Larsen T. Alves D.A. Coberley S.S. Bavari S. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses Expert Rev Vaccines 7 2008 417 429 10.1586/14760584.7.4.417 18444889 · DOI
  52. Thi E.P. Mire C.E. Ursic-Bedoya R. Geisbert J.B. Lee A.C.H. Agans K.N. Marburg virus infection in nonhuman primates: therapeutic treatment by lipid-encapsulated siRNA Sci Transl Med 6 2014 ra116 10.1126/scitranslmed.3009706 PMC4502585 25143366 · DOI
  53. Ursic-Bedoya R. Mire C.E. Robbins M. Geisbert J.B. Judge A. MacLachlan I. Protection against lethal Marburg virus infection mediated by lipid encapsulated small interfering RNA J Infect Dis 209 2014 562 570 23990568 PMC3903369
  54. Warfield K.L. Aman J. Advances in virus-like particle vaccines for filoviruses J Infect Dis 204 Suppl. 3 2011 S1053 10.1093/infdis/jir346 21987741 PMC3189993 · DOI
  55. Warren T.K. Wells J. Panchal R.G. Stuthman K.S. Garza N.L. Van Tongeren S.A. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430 Nature 508 2014 402 405 10.1038/nature13027 24590073 PMC7095208 · DOI
  56. Warren T.K. Whitehouse C.A. Wells J. Welch L. Charleston J.S. Heald A. Delayed time to treatment of an antisense morpholino oligomer is effective against lethal Marburg virus infection in cynomolgus macaques PLoS Neglect Trop Dis 10 2016 1 18 10.1371/journal.pntd.0004456 PMC4764691 26901785 · DOI
  57. WHO Ebola Response Team Agua-Agum J. Ariyarajah A. Blake I.M. Cori A. Donnelly C.A. Ebola virus disease among children in West Africa N Engl J Med 372 13 2015 1274 1277 10.1056/NEJMc1415318 PMC4393247 25806936 · DOI
  58. Woolsey C. Geisbert J.B. Matassov D. Agans K.N. Borisevich V. Cross R.W. Postexposure efficacy of recombinant vesicular stomatitis virus vectors against high and low doses of Marburg virus variant Angola in nonhuman primates J Infect Dis 218 2018 S582 S587 10.1093/infdis/jiy293 29939296 PMC6249565 · DOI

Cited by

Sorted by citations

Authors
Kortepeter, M. G., Dierberg, K., Shenoy, E. S., & Cieslak, T. J.
Affiliations
  • University of Nebraska Medical Center (US)
  • Bellevue Hospital Center (US)
  • Massachusetts General Hospital (US)
Corresponding author
Kortepeter, Mark G.
ORCID
Venue
International Journal of Infectious Diseases
Publisher
Elsevier BV
Published
2020-10
Volume
99
Pages
233-242
ISSN
1201-9712 (ISSN-L)
DOI
10.1016/j.ijid.2020.07.042
PMC
PMC7397931
OpenAlex
W3047616385
Cited by
160
References
2
Citations by year
2026: 24 · 2025: 28 · 2024: 37 · 2023: 47 · 2022: 21 · 2021: 2 · 2020: 1
FWCI
0.84
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Infectious Diseases (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
United States Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (5 U3REP170552-003-02)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Viral Infections and Outbreaks Research
  • Health Sciences › Medicine › Infectious Diseases › Viral Infections and Vectors
  • Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
Keywords
Marburg virus disease, countermeasures, vaccines, antiviral therapy, non-human primates, pathogenesis, clinical features, diagnostics, disaster preparedness, hemorrhagic fever
MeSH terms
Animals, Humans, Marburg Virus Disease, Viral Vaccines, Marburgvirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review